[HTML][HTML] Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer
N Epaillard, J Bassil, B Pistilli - Cancer Treatment Reviews, 2023 - Elsevier
Breast cancer is one of the main cause of cerebral and leptomeningeal metastases, the
prognosis of which remains poor to this day. Most studies excluded patients with active brain …
prognosis of which remains poor to this day. Most studies excluded patients with active brain …
Antibody–drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis
I Michelon, MI Dacoregio, M Vilbert… - Therapeutic …, 2024 - journals.sagepub.com
Background: Until recently, targeted therapies have failed to benefit patients with human
epidermal growth factor receptor 2 (HER2)-low-expressing breast cancer (BC) …
epidermal growth factor receptor 2 (HER2)-low-expressing breast cancer (BC) …
Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World …
S Sharman Moser, L Apter, I Livnat… - … Cancer: Targets and …, 2024 - Taylor & Francis
Background In this observational study, we analyzed the treatment patterns and clinical
outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive …
outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive …
[HTML][HTML] Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis
K Liang, JL Feliciano, KA Marrone, JC Murray… - ESMO open, 2024 - Elsevier
Background Brain metastasis (BRM) is uncommon in gastroesophageal cancer. As such,
clinicopathologic and molecular determinants of BRM and impact on clinical outcome …
clinicopathologic and molecular determinants of BRM and impact on clinical outcome …
HER2-low Breast Cancer: Now and in the Future
S Kang, SB Kim - Cancer Research and Treatment, 2024 - e-crt.org
Breast cancer is a heterogeneous disease, and its subtypes are characterized by hormone
receptor and human epidermal growth factor receptor 2 (HER2) expression status.“HER2 …
receptor and human epidermal growth factor receptor 2 (HER2) expression status.“HER2 …
[PDF][PDF] RESEARCH AND TREATMENT
WY Park, YC Ahn, DH Lee, HY Lee, EK Chie… - 2024 - e-crt.org
Cancer Research and Treatment is a peer-reviewed open access publication of the Korean
Cancer Association, Korean Society of Medical Oncology, and Korean Association for Lung …
Cancer Association, Korean Society of Medical Oncology, and Korean Association for Lung …
Trastuzumab Deruxtecan for the Treatment of HER2-low Advanced or Metastatic Breast Cancer.
T Yamashita - touchREVIEWS in Oncology & Haematology, 2024 - search.ebscohost.com
T rastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate widely used in human
epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), based …
epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), based …